

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA tisagenlecleucel-T for B-cell acute lymphoblastic
leukaemia [ID1167]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

No equality issues were identified at consultation. However, consultation comments from ID446 (Arsenic trioxide for treating acute promyelocytic leukaemia) identified a subgroup that is also potentially relevant in this appraisal: Jehovah's witnesses for whom chemotherapy is not suitable.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

Blood support or haematopoietic stem cell transplantation are not acceptable to some religious groups such as Jehovah's witnesses these patients would receive best supportive care

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

A Jehovah's witness group has been added to the commentators in the provisional matrix.

Approved by Associate Director (name): ...Frances Sutcliffe.....

Date: 13/03/2018